Abstract: Disclosed are methods of treating colorectal cancer that involve administering a composition comprising an effective amount of miR-451a to cells in the colorectal cancer and further treating the colorectal cancer cells with ionizing radiation. Also disclosed are methods of predicting whether a colorectal cancer in a subject will respond to ionizing radiation. These methods involve measuring the RNA expression of miR-451a, miR-1322, miR-133-3p, miR-1, miR-205-5p, miR-4521, CAB39, EMSY, or MEX3C in the sample and measuring the RNA expression of the same marker in a control.

Abstract: MicroRNA inhibitors as anti-cancer therapeutics are described. The microRNA inhibitors can inhibit microRNA-15a and can mimic the effects of higher dose radiation at lower doses. Other benefits are also described.

Abstract: Disclosed are methods of treating colorectal cancer that involve administering a composition comprising an effective amount of miR-451a to cells in the colorectal cancer and further treating the colorectal cancer cells with ionizing radiation. Also disclosed are methods of predicting whether a colorectal cancer in a subject will respond to ionizing radiation. These methods involve measuring the RNA expression of miR-451a, miR-1322, miR-133-3p, miR-1, miR-205-5p, miR-4521, CAB39, EMSY, or MEX3C in the sample and measuring the RNA expression of the same marker in a control.

Abstract: MicroRNA inhibitors as anti-cancer therapeutics are described. The microRNA inhibitors can inhibit microRNA-15a and can mimic the effects of higher dose radiation at lower doses. Other benefits are also described.

Abstract: Technology is described for migrating connections for Internet of Things (IoT) devices. Data packets may be received from an IoT device for forwarding to a first physical host in a computing service environment. A determination to migrate the connection for the IoT device from the first physical host to a second physical host in the computing service environment may be performed when a throughput of the data packets received from the IoT device for the first physical host exceeds a defined threshold. A connection migration procedure may be initiated to migrate the connection for the IoT device from the first physical host to the second physical host. The connection migration procedure may include an exchange of session state information for the IoT device from the first physical host to the second physical host to enable the migration of the connection to the second physical host.

Abstract: In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell.

Abstract: Pharmaceutical compositions comprising one or more of miR-494-3p, miR-99b-5p, and/or miR-21-3p and a pharmaceutically acceptable carrier as well as methods of using said compositions to treat cancer characterized by aberrant activity of an MRN complex.

Abstract: In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell.

Abstract: In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell.

Abstract: Technologies are described herein for providing item registration services to customers. A customer of an electronic marketplace system is provided with functionality to submit a request to register an item when purchasing the item through an electronic marketplace system. The customer may choose assisted direct registration for the item using his/her identity information or indirect registration using identity information of the electronic marketplace system. Once the purchase order is received and has been processed, a registration request may be generated based on item information and customer information contained in the purchase order, and submitted to the corresponding manufacturer. When indirect registration is selected, the customer information is replaced with the information of the electronic marketplace system before the registration request is submitted to the manufacturer.

Abstract: In alternative embodiments, the invention provides compositions and methods comprising use of microRNAs and microRNA inhibitors to modulate blood vessel growth (angiogenesis), e.g., act as anti-angiogenic agents, and modulate cell and tumor microenvironment patterning, cancer cell and tumor growth and malignant disease (metastasis). In alternative embodiments, the invention provides compositions and methods that can sensitize blood vessels, e.g., tumor blood vessels, to radiation and agents and chemotherapies that cause DNA damage.

Abstract: In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell.

Abstract: In alternative embodiments, the invention provides compositions and methods comprising use of microRNAs and microRNA inhibitors to modulate blood vessel growth (angiogenesis), e.g., act as anti-angiogenic agents, and modulate cell and tumor microenvironment patterning, cancer cell and tumor growth and malignant disease (metastasis). In alternative embodiments, the invention provides compositions and methods that can sensitize blood vessels, e.g., tumor blood vessels, to radiation and agents and chemotherapies that cause DNA damage.

Abstract: Architecture for restoring nodes. After restoring a node, fix-up occurs to make the node appears as a different node than before the restore operation. The node appears as a new node, which new node knows the data up to a certain point from when the new node had the prior identity. This allows for new changes generated by the new node to flow to the other nodes in the topology, as well as have the changes that the prior identity sent to other nodes flow back to the new node. In other words, the architecture maintains information to create the new node in the topology while maintaining prior data knowledge. Additionally, item level metadata of associated data items is updated to correlate with the updated data items so that changes can be correctly enumerated and applied. This metadata update occurs across scopes of which the data items are included.

Abstract: Architecture for restoring nodes. After restoring a node, fix-up occurs to make the node appears as a different node than before the restore operation. The node appears as a new node, which new node knows the data up to a certain point from when the new node had the prior identity. This allows for new changes generated by the new node to flow to the other nodes in the topology, as well as have the changes that the prior identity sent to other nodes flow back to the new node. In other words, the architecture maintains information to create the new node in the topology while maintaining prior data knowledge. Additionally, item level metadata of associated data items is updated to correlate with the updated data items so that changes can be correctly enumerated and applied. This metadata update occurs across scopes of which the data items are included.